Fosun International Ltd. (00656:HK) and London-based healthcare and life science company Arix Bioscience plc (LSE:ARIX) have jointly announced a strategic agreement to develop and commercialize new clinical therapies for patients with a focus on the Chinese markets.
Financial services firm Orix Corp has led a RMB250 million (US$39 million) series A round in Innostic, a Chinese medical consumable supply chain management platform.
Italian biomedical equipment maker Esaote S.p.A. announced that a consortium of Chinese investors, including Yunfeng Capital co-founded by Alibaba’s Jack Ma, have entered into definitive agreements to acquire the entire share capital of the company.
Vision Plus Capital, a Hangzhou-based venture capital firm, has led a RMB200 million (US$30 million) series B round in Etong Healthcare, a third-party health examination service provider.
An artificial intelligence enabled robot has passed the written test of China’s national medical licensing examination for the first time, marking another milestone in the quest for AI technology to match or surpass human intelligence. Named Xiaoyi, the robot developed by Tsinghua University and Chinese information technology firm iFlytek, achieved a score of 456, 96 points higher than the required mark of 360 points, according to a company announcement.
China’s Taikang Investment has led a US$32 million series B round in EOC Pharma Group, an oncology-focused development company, through its healthcare and consumer industry-focused Shandong State-owned Taikang Industry Development Fund.
The Chinese government announced a new policy directive to further encourage innovation in new drug development and medical device yesterday, making significant changes to existing policies to spur an already thriving healthcare sector in the country.
Legend Capital and Zhongjinqichen, a healthcare, technology and consumer-focused private equity fund under China International Capital Co., Ltd have lead a RMB250 million (US$38 million) series B round in Bellen, a Chinese medical contract research organization (CRO).
XW Laboratories Inc., a Chinese biopharmaceutical research and development company focused on neurological disorders, has raised US$17.5 million in a series B financing led by Elements Capital and WI Harper. New investo KTB Network, and all existing investors KPCB China, Johnson & Johnson Innovation and WuXi Venture, also participated.
Qiming Venture Partners has led a RMB120 million (US$18 million) series B round in Infervision, a Chinese artificial intelligence start-up developing medical imaging technology.
China Healthcare Investor Forum 2017, hosted by China Money Network and sponsored by Ernst & Young, was successfully held on September 19 at the Shanghai World Financial Center with four prominent speakers discussing investment opportunities and challenges in China’s booming healthcare sector.
GTJA Investment Group, a Shenzhen-based private equity firm focused on the healthcare sector in China, has led a US$30 million series B round in Wellem, a pediatric clinic franchise operator currently running 11 branches in China.
Chinese medical device maker Basecare, which specializes in manufacturing devices for embryonic pre-implantation genetic screening, has raised a RMB100 million (US$14 million) series B round from unnamed investors.
Chinese investment firm Yingke Private Equity has invested RMB100 million (US$14 million) in Shanghai Sanyou Medical Co., Ltd., an orthopedic medical device developer.
Healthcare-dedicated investment firm OrbiMed has closed its third Asia-focused private equity fund, OrbiMed Asia Partners III, LP, with approximately US$551 million in capital commitments.
SinoVision Technologies (Beijing) Co., Ltd., a Chinese medical technology start-up developing computed tomography (CT) scanners, has raised a RMB200 million (US$29 million) new funding round from HG Capital, Qiming Venture Partners and little-known Chinese healthcare investment firm Yili Fuyi Daohe.
Arrail Dental, a Chinese private dental service provider with nearly 100 private dental clinics in the country, has raised a US$90 million series D round from Goldman Sachs and Chinese private equity firm Hillhouse Capital Group.
The GTJA Investment Group has led a RMB300 million (US$45 million) series B round in Akeso Biopharma, a Chinese innovative biotechnology company.
SDIC Fund Management Company Ltd., a private equity firm majority owned by China’s State Development & Investment Corporation (SDIC), has led a RMB440 million (US$66 million) series D round in CF PharmaTech Inc., a Chinese company developing drugs to treat respiratory diseases.
Private clinic franchise Distinct Healthcare has raised a US$40 million series C round from Matrix Partners China, Tiantu Capital, China International Capital Co., Ltd, Qianhai Fund of Funds, and Shuimu Fund.
Shanghai-based biopharmaceutical company Zai Lab, founded by Samantha Du, a former managing director at Sequoia Capital, has filed to raise up to US$115 million in an initial public offering on the NASDAQ.
Lilly Asia Ventures, a healthcare-focused venture capital firm backed by global pharmaceutical giant Eli Lilly & Co., has closed its fourth healthcare fund at a US$450 million hard cap.
中文版请点击这里 The China Healthcare Investor Forum 2017, hosted by China Money Network, will feature the nation’s brightest and most successful healthcare investors discussing key opportunities and challenges in one of the world’s hottest investment sectors. Register now to join leading deal makers from KPCB, CDH Investments, Lilly Asia Ventures and OrbiMed for an intimate and informative panel discussion and open Q&A. Then network with other attendees from top Chinese investment firms and healthcare company executives. Limited seats available. Click Here …
C-Bridge Capital, a Shanghai-based private equity firm focused on China’s healthcare sector, has closed its second healthcare fund, C-Bridge Healthcare Fund II, at a US$400 million hard cap.
iCarbonX, an artificial intelligence-enabled health data mining start-up in China, has participated in a US$8.4 million series B financing round in U.S. healthcare company HealthLoop, with an eye to integrate the American firm’s patient-generated data to its own data mining efforts.
Hong Kong stock exchange-listed Alibaba Health Information Technology Ltd. said it would acquire a nutritional supplement unit of its parent Alibaba Group for HK$3.8 billion (US$490 million), according to a company announcement.
China-focused investment firm Hillhouse Capital Group has led a RMB380 million (US$55 million) series C financing round in Yitu Technology, a Shanghai-based artificial intelligence start-up specialized in the field of machine vision, big data and advanced hardware.
Oriza Seed Venture Capital, an early stage investment unit under Oriza Holdings, has led a US$25 million series A round in EpimAb Biotherapeutics, a Shanghai-based biopharmaceutical company specializing in bispecific antibodies.
CITIC Capital and a private equity fund jointly established by the Agricultural Bank of China and the Wuxi government have led a RMB250 million (US$36.3 million) series B round in Beijing-based mobile health management platform More Health.
China’s Dalian Wanda Group Co., Ltd., has signed a strategic partnership agreement with the government of Chengdu to invest RMB70 billion (US$10 billion) to create a healthcare hub in the city, located in Western Sichuan province.
Redpoint Ventures and Sinovation Ventures have led a RMB100 million (US$14 million) series B round in Xiaolu Yiguan, an online platform connecting traditional Chinese medicine providers with consumers.